Introduction/Background A high platelet-lymphocyte ratio (PLR) is a marker of systemic inflammation and, together with the neutrophil-lymphocyte ratio (NLR), is associated with poor outcomes in several cancers. We investigated the prognostic value of PLR and other systemic inflammatory markers, such as NLR, systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), in Endometrial carcinoma (EC) patients undergoing surgical resection.

Methodology We derived PLR, NLR, SII, and SIRI from a retrospective chart review of 298 consecutive EC patients. The complete blood count examined in the immediate preoperative period was used to compute PLR, NLR, SII, and SIRI. We analyzed the relationship between these systemic inflammatory markers and the clinicopathologic characteristics, and overall survival (OS) of patients.

Results In the univariate analysis, high NLR, SII and SIRI were significantly associated with worse OS (all p < 0.05). In the multivariate analysis, high SII showed trend for poor outcome but without statistically significance (p=0.056). In the subgroup analysis of patients with advanced FIGO2023 stage (n=51), a multivariate analysis revealed that the SII was an independent predictor of OS (HR 3.30, 95% CI 1.28–8.86 for OS) and progression free survival (PFS, HR 4.02, 95% CI 1.44–11.22).

Conclusion Our findings suggest that in patients with advanced EC, the pretreatment SII is an independent predictor of OS and PFS. The SII is a readily available biomarker that will improve prognostication and risk stratification in advanced EC.

Disclosures No conflict of interest.